A pair of young biotech execs snag a mega-round for their late-stage ALS drug as the FDA signals a more flexible approach to an OK
Five years after Justin Klee and Josh Cohen got a little seed cash from the late Boston biotech legend Henri Termeer to see if they could do something serious with a college science project they had cooked up for ALS, the two young entrepreneurs have assembled an executive team and a syndicate willing to put up a mega-round for the pivotal test while setting the stage on commercialization.
And while they’re already filing for an OK in Canada and Europe this year, the co-CEOs at Amylyx have also engaged in talks to see if the FDA may prove open to a quick pitch now that Biogen’s Aduhelm has broken through in Alzheimer’s with its fragmentary collection of data.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 113,300+ biopharma pros reading Endpoints daily — and it's free.